Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.
Original title: “Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial”
AbbVie and Genmab’s bispecific antibody blew analyst expectations out of the water with a 51% improvement in progression-free survival when used alongside a standard frontline regimen in diffuse large B cell lymphoma—potentially setting up a battle with Roche's Polivy.
Original title: “AbbVie, Genmab's Epkinly sets ‘new standard of care’ in first-line lymphoma in Phase 3”
prognostic factors and survival in hhv8 positive diffuse large b cell lymphoma a national cancer database analysis
Original title: “Prognostic factors and survival in HHV8 positive diffuse large B cell lymphoma: a national cancer database analysis.”
hemophagocytic lymphohistiocytosis as the initial presentation of occult diffuse large b cell lymphoma a diagnostic challenge
Original title: “Hemophagocytic Lymphohistiocytosis As the Initial Presentation of Occult Diffuse Large B-cell Lymphoma: A Diagnostic Challenge.”
peritoneal lymphomatosis mimicking complicated hydatid cyst on imaging a rare presentation of diffuse large b cell lymphoma
Original title: “Peritoneal lymphomatosis mimicking complicated hydatid cyst on imaging: A rare presentation of diffuse large B-cell lymphoma.”
myd88l265p mutation is a highly specific marker for the nongcb abc dlbcl molecular subtype
Original title: “MYD88L265P mutation is a highly specific marker for the nonGCB/ABC DLBCL molecular subtype.”
In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in patients with diffuse large B cell lymphoma, casting doubt on its value as a second-line treatment in this indication.
Original title: “ADC Therapeutics nosedives on 27 deaths in confirmatory trial for lymphoma drug”
extranodal male genital involvement with diffuse large b cell lymphoma
Original title: “Extranodal Male Genital Involvement With Diffuse Large B-Cell Lymphoma.”
multidisciplinary diagnosis and treatment of thyroid diffuse large b cell lymphoma with tracheal invasion a case report
Original title: “Multidisciplinary diagnosis and treatment of thyroid diffuse large B cell lymphoma with tracheal invasion: a case report.”
benign thyroid nodule mimicking residual disease on positron emission tomography computed tomography in a patient with concurrent thyroid and gastric diffuse large b cell lymphoma the value of ultrasound guided biopsy
Original title: “Benign thyroid nodule mimicking residual disease on positron emission tomography/computed tomography in a patient with concurrent thyroid and gastric diffuse large B-cell lymphoma: the value of ultrasound-guided biopsy.”
breast implant associated epstein barr virus positive diffuse large b cell lymphoma
Original title: “Breast Implant-Associated Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma.”